Eiki Ichihara1, Daijiro Harada2, Koji Inoue3, Ken Sato4, Shinobu Hosokawa5, Daizo Kishino6, Kazuhiko Watanabe7, Nobuaki Ochi8, Naohiro Oda9, Naofumi Hara10, Katsuyuki Hotta11, Yoshinobu Maeda10, Katsuyuki Kiura12. 1. Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. Electronic address: ichiha-e@md.okayama-u.ac.jp. 2. Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. 3. Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan. 4. Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan. 5. Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan. 6. Department of Respiratory Medicine, Himeji Red Cross Hospital, Himeji, Japan. 7. Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan. 8. Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan. 9. Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan. 10. Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. 11. Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan. 12. Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Abstract
OBJECTIVES: Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. MATERIALS AND METHODS: The medical records of NSCLC patients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. RESULTS: A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). CONCLUSION: BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.
OBJECTIVES: Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (NSCLC) treated with programmed cell death protein 1 (PD-1)/ programmed death-ligand 1(PD-L1) inhibitors. The purpose of this study was to investigate the relationship between BMI and the efficacy of ICI treatment in patients with advanced NSCLC. MATERIALS AND METHODS: The medical records of NSCLCpatients who received PD-1/PD-L1 antibody monotherapy at nine institutions between December 2015 and May 2018 were reviewed retrospectively. The effect of BMI was investigated in two cohorts. Cohort 1 included patients with NSCLCs with high PD-L1 expression (≥ 50 %) treated with pembrolizumab as first-line therapy, and cohort 2 included patients with NSCLCs treated with nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment. RESULTS: A total of 513 from nine institutions were analyzed (84 in cohort 1, 429 in cohort 2). Using a BMI cut-off value of 22 kg/m2, which is an ideal BMI in our country (high BMI:22.0 and low BMI:22.0), there was no significant difference in the PFS or OS between the high and low BMI patients in cohort 1. However, in cohort 2, survival was significantly longer in patients with a high versus low BMI (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021). CONCLUSION: BMI was significantly associated with the efficacy of ICIs in patients with NSCLC treated with second- or later-line PD-1/PD-L1 inhibitors in our cohort.
Authors: Alessio Cortellini; Biagio Ricciuti; Marcello Tiseo; Emilio Bria; Giuseppe L Banna; Joachim Gjv Aerts; Fausto Barbieri; Raffaele Giusti; Diego L Cortinovis; Maria R Migliorino; Annamaria Catino; Francesco Passiglia; Mariangela Torniai; Alessandro Morabito; Carlo Genova; Francesca Mazzoni; Vincenzo Di Noia; Diego Signorelli; Alain Gelibter; Mario Alberto Occhipinti; Francesca Rastelli; Rita Chiari; Danilo Rocco; Alessandro Inno; Michele De Tursi; Pietro Di Marino; Giovanni Mansueto; Federica Zoratto; Francesco Grossi; Marco Filetti; Pamela Pizzutilo; Marco Russano; Fabrizio Citarella; Luca Cantini; Giada Targato; Olga Nigro; Miriam G Ferrara; Sebastiano Buti; Simona Scodes; Lorenza Landi; Giorgia Guaitoli; Luigi Della Gravara; Fabrizio Tabbò; Serena Ricciardi; Alessandro De Toma; Alex Friedlaender; Fausto Petrelli; Alfredo Addeo; Giampiero Porzio; Corrado Ficorella Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751
Authors: Murtaza Ahmed; Mitchell S von Itzstein; Thomas Sheffield; Shaheen Khan; Farjana Fattah; Jason Y Park; Vinita Popat; Jessica M Saltarski; Yvonne Gloria-McCutchen; David Hsiehchen; Jared Ostmeyer; Saad A Khan; Nazima Sultana; Yang Xie; Quan-Zhen Li; Edward K Wakeland; David E Gerber Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751